Cellipont Bioservices and Secretome Therapeutics are set to enter a collaboration in the manufacture of the latter’s cellular therapy, STM-01. The collaboration will see Cellipont offering technology ...
Zacks.com on MSN1h
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure StudyShares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...
The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome ...
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...
Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...
Cedars-Sinai shared the story of a Hollywood writer who kept his appointment for mitral valve surgery right after escaping ...
The Metrolinx award includes an initial firm order for 80 45-foot D45 CRT diesel commuter coaches along with a number of options that were added to NFI's fourth quarter 2024 backlog. The contract also ...
Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback